• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Intracranial regression of an advanced basal cell carcinoma using sonidegib and itraconazole after failure with vismodegib.

作者信息

Yoon Jaeyoung, Apicelli Anthony J, Pavlopoulos Tricia V

机构信息

Forefront Dermatology, St. Louis, Missouri.

Department of Radiation Oncology, Washington University School of Medicine, Siteman Cancer Center, St. Louis, Missouri.

出版信息

JAAD Case Rep. 2017 Dec 18;4(1):10-12. doi: 10.1016/j.jdcr.2017.11.001. eCollection 2018 Jan.

DOI:10.1016/j.jdcr.2017.11.001
PMID:29387745
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5771754/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edc8/5771754/7800fa52d561/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edc8/5771754/7800fa52d561/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/edc8/5771754/7800fa52d561/gr1.jpg

相似文献

1
Intracranial regression of an advanced basal cell carcinoma using sonidegib and itraconazole after failure with vismodegib.维莫德吉治疗失败后，使用索尼德吉和伊曲康唑使晚期基底细胞癌颅内病灶消退
JAAD Case Rep. 2017 Dec 18;4(1):10-12. doi: 10.1016/j.jdcr.2017.11.001. eCollection 2018 Jan.
2
Vismodegib, itraconazole and sonidegib as hedgehog pathway inhibitors and their relative competencies in the treatment of basal cell carcinomas.维莫德吉、伊曲康唑和索尼德吉作为刺猬信号通路抑制剂及其在治疗基底细胞癌方面的相对效能。
Crit Rev Oncol Hematol. 2016 Feb;98:235-41. doi: 10.1016/j.critrevonc.2015.11.006. Epub 2015 Nov 21.
3
Sonidegib: mechanism of action, pharmacology, and clinical utility for advanced basal cell carcinomas.索尼德吉：晚期基底细胞癌的作用机制、药理学及临床应用
Onco Targets Ther. 2017 Mar 16;10:1645-1653. doi: 10.2147/OTT.S130910. eCollection 2017.
4
An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib.一项研究者发起的关于索尼德吉治疗对维莫德吉耐药的晚期基底细胞癌患者的开放标签试验。
Clin Cancer Res. 2016 Mar 15;22(6):1325-9. doi: 10.1158/1078-0432.CCR-15-1588. Epub 2015 Nov 6.
5
Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis.索尼替尼和维莫德吉治疗儿科和成人 MB 患者的 I 期和 II 期临床试验：系统评价和荟萃分析。
Acta Neuropathol Commun. 2019 Jul 30;7(1):123. doi: 10.1186/s40478-019-0773-8.
6
The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma.BOLT 研究：隆地替尼治疗基底细胞癌的 12 个月分析：一项评价晚期基底细胞癌患者接受 sonidegib 治疗的 II 期、随机、双盲研究。
J Am Acad Dermatol. 2016 Jul;75(1):113-125.e5. doi: 10.1016/j.jaad.2016.02.1226. Epub 2016 Apr 7.
7
Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma.Sonic Hedgehog 通路抑制在晚期基底细胞癌治疗中的应用。
Curr Treat Options Oncol. 2019 Nov 26;20(11):84. doi: 10.1007/s11864-019-0683-9.
8
Sonidegib phosphate: new approval for basal cell carcinoma.磷酸索尼德吉：基底细胞癌的新批准药物
Drugs Today (Barc). 2016 May;52(5):295-303. doi: 10.1358/dot.2016.52.5.2470697.
9
Sonidegib for the treatment of advanced basal cell carcinoma.索尼德吉用于治疗晚期基底细胞癌。
Expert Opin Pharmacother. 2016 Oct;17(14):1963-8. doi: 10.1080/14656566.2016.1225725. Epub 2016 Aug 29.
10
Pharmacological evaluation of a series of smoothened antagonists in signaling pathways and after topical application in a depilated mouse model.一系列 smoothened 拮抗剂在信号通路中的药理学评价及其在脱毛小鼠模型中的局部应用。
Pharmacol Res Perspect. 2016 Mar 4;4(2):e00214. doi: 10.1002/prp2.214. eCollection 2016 Apr.

引用本文的文献

1
Therapeutic Approaches for Advanced Basal Cell Carcinoma: A Comprehensive Review.晚期基底细胞癌的治疗方法：综述
Cancers (Basel). 2024 Dec 29;17(1):68. doi: 10.3390/cancers17010068.
2
Biomarkers in Cutaneous Keratinocyte Carcinomas.皮肤角质形成细胞癌中的生物标志物
Dermatol Ther (Heidelb). 2024 Aug;14(8):2039-2058. doi: 10.1007/s13555-024-01233-w. Epub 2024 Jul 20.
3
Evaluation of the Tolerability of Hedgehog Pathway Inhibitors in the Treatment of Advanced Basal Cell Carcinoma: A Narrative Review of Treatment Strategies.

本文引用的文献

1
Pembrolizumab versus Ipilimumab in Advanced Melanoma.帕博利珠单抗对比伊匹单抗用于晚期黑色素瘤。
N Engl J Med. 2015 Jun 25;372(26):2521-32. doi: 10.1056/NEJMoa1503093. Epub 2015 Apr 19.
2
Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma.smoothened（SMO）受体突变决定了基底细胞癌对维莫德吉的耐药性。
Mol Oncol. 2015 Feb;9(2):389-97. doi: 10.1016/j.molonc.2014.09.003. Epub 2014 Sep 26.
3
Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma.
评估 Hedgehog 通路抑制剂治疗晚期基底细胞癌的耐受性：治疗策略的叙述性综述。
Am J Clin Dermatol. 2024 Sep;25(5):779-794. doi: 10.1007/s40257-024-00870-3. Epub 2024 Jun 19.
4
Long-Term Management of Advanced Basal Cell Carcinoma: Current Challenges and Future Perspectives.晚期基底细胞癌的长期管理：当前挑战与未来展望
Cancers (Basel). 2022 Sep 20;14(19):4547. doi: 10.3390/cancers14194547.
5
Experience with sonidegib in patients with advanced basal cell carcinoma: case reports.晚期基底细胞癌患者使用索尼德吉的经验：病例报告
Drugs Context. 2022 May 23;11. doi: 10.7573/dic.2022-3-8. eCollection 2022.
6
Switching Hedgehog inhibitors and other strategies to address resistance when treating advanced basal cell carcinoma.在治疗晚期基底细胞癌时，更换刺猬信号通路抑制剂及其他策略以应对耐药性。
Oncotarget. 2021 Sep 28;12(20):2089-2100. doi: 10.18632/oncotarget.28080.
7
Known and new facts on basal cell carcinoma.基底细胞癌的已知和新事实。
J Dtsch Dermatol Ges. 2021 Jul;19(7):1021-1041. doi: 10.1111/ddg.14580.
8
Vismodegib dose reduction effective when combined with itraconazole for the treatment of advanced basal cell carcinoma.维莫德吉与伊曲康唑联合用于治疗晚期基底细胞癌时，剂量减少有效。
JAAD Case Rep. 2020 Nov 24;7:107-109. doi: 10.1016/j.jdcr.2020.11.014. eCollection 2021 Jan.
9
Inhibition of the hedgehog pathway for the treatment of cancer using Itraconazole.使用伊曲康唑抑制刺猬信号通路治疗癌症。
Onco Targets Ther. 2019 Aug 23;12:6875-6886. doi: 10.2147/OTT.S223119. eCollection 2019.
10
Hedgehog Pathway Inhibition for the Treatment of Basal Cell Carcinoma. hedgehog 通路抑制治疗基底细胞癌。
Target Oncol. 2019 Jun;14(3):253-267. doi: 10.1007/s11523-019-00648-2.
开放性、探索性 II 期临床试验：口服伊曲康唑治疗基底细胞癌。
J Clin Oncol. 2014 Mar 10;32(8):745-51. doi: 10.1200/JCO.2013.49.9525. Epub 2014 Feb 3.
4
Unraveling the therapeutic potential of the Hedgehog pathway in cancer.揭示 Hedgehog 通路在癌症治疗中的潜力。
Nat Med. 2013 Nov;19(11):1410-22. doi: 10.1038/nm.3389. Epub 2013 Nov 7.
5
Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists.伊曲康唑和三氧化二砷抑制 Hedgehog 通路的激活和获得性对 smoothened 拮抗剂耐药相关的肿瘤生长。
Cancer Cell. 2013 Jan 14;23(1):23-34. doi: 10.1016/j.ccr.2012.11.017. Epub 2013 Jan 3.
6
Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome.抑制基底细胞痣综合征患者的 hedgehog 通路。
N Engl J Med. 2012 Jun 7;366(23):2180-8. doi: 10.1056/NEJMoa1113538.
7
Efficacy and safety of vismodegib in advanced basal-cell carcinoma.维莫德吉治疗晚期基底细胞癌的疗效和安全性。
N Engl J Med. 2012 Jun 7;366(23):2171-9. doi: 10.1056/NEJMoa1113713.
8
Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.晚期基底细胞癌中刺猬信号通路的抑制作用。
N Engl J Med. 2009 Sep 17;361(12):1164-72. doi: 10.1056/NEJMoa0905360. Epub 2009 Sep 2.